Optimizing Masks and Random Screening Test Usage within K-12 Schools.

To compare the accuracy measures of the random glucose test and the 50-g glucose challenge test as screening tests for gestational diabetes mellitus (GDM). In this prospective cohort study, pregnant women without preexisting diabetes in two perinatal centers in the Netherlands underwent a random glucose test and a 50-g glucose challenge test between 24 and 28 weeks of gestation. If one of the screening tests exceeded predefined threshold values, the 75-g oral glucose tolerance test (OGTT) was performed within 1 week. Furthermore, the OGTT was performed in a random sample of women in whom both screening tests were normal. GDM was considered present when the OGTT (reference test) exceeded predefined threshold values. Receiver operating characteristic (ROC) analysis was used to evaluate the performance of the two screening tests. The results were corrected for verification bias. We included 1,301 women. The OGTT was performed in 322 women. After correction for verification bias, the random glucose test showed an area under the ROC curve of 0.69 (95% CI 0.61-0.78), whereas the glucose challenge test had an area under the curve of 0.88 (0.83-0.93). There was a significant difference in area under the curve of the two tests of 0.19 (0.11-0.27) in favor of the 50-g glucose challenge test. In screening for GDM, the 50-g glucose challenge test is more useful than the random glucose test.

This article presents a study on the satellite random vibration testing method founded on a screening stress model for batch production satellites, to optimize the mechanical testing items for these satellites and reduce development costs. It begins by introducing the mathematical model for random vibration stress screening and analyzes the screening effectiveness of satellites in both noise test and random vibration test separately. Subsequently, using the responses of satellites in various directions during noise testing as a reference, the article employs a screening degree equivalent method to analyze the screening effectiveness and duration of random vibration testing. Finally, a unidirectional random process inspection test method specifically for batch production satellites is proposed.

Urine testing for drug use in the workplace is now widespread, with the prevalence of positive drug tests in the work force being 0% to 15%. The prevalence of marijuana use is highest of the illicit drugs being tested. Highly prevalent drugs can be reliably tested. Although it is prudent to rid the workplace of drug use, there is little scientific study on the relationship of drug use and workplace outcomes, such as productivity and safety. Probable-cause testing and preemployment testing are the most common applications. Random testing has been less accepted owing to its higher costs, unresolved legal issues, and predictably poor test reliability. Legal issues have focused on the right to privacy, policy agreements, discrimination, and the lack of due process. The legal cornerstone of a good program is a policy that is planned and agreed on by both labor and management, which serves both as a contract and as a procedure in which expectations and consequences are known. Moreover, NIDA is certifying laboratories doing employee drug testing. Testing methods, when done correctly, are less prone to error than in the past, but screening tests can be defeated by adulterants. Although the incidence of false-positive results is low, such tests are less reliable when the prevalence of drug abuse is also low.

A Need to Establish Programs to Detect and Prevent Drug Diversion

Efforts to reduce controlled-substance abuse by anesthesiologists have focused on education and tighter regulation of controlled substances. However, the efficacy of these approaches remains to be determined. Our hypotheses were that the reported incidence of controlled-substance abuse is unchanged from previous reports and that the control and accounting process involved in distribution of operating room drugs has tightened. We focused our survey on anesthesiology programs at American academic medical centers. Surveys were sent to the department chairs of the 133 US anesthesiology training programs accredited at the end of 1997. There was a response rate of 93%. The incidence of known drug abuse was 1.0% among faculty members and 1.6% among residents. Fentanyl was the controlled substance most often abused. The number of hours of formal education regarding drug abuse had increased in 47% of programs. Sixty-three percent of programs surveyed had tightened their methods for dispensing, disposing of, or accounting for controlled substances. The majority of programs (80%) compared the amount of controlled substances dispensed against individual provider usage, whereas only 8% used random urine testing. Sixty-one percent of departmental chairs indicated that they would approve of random urine screens of anesthesia providers. This survey indicates that the frequency of controlled substance abuse among anesthesiologists has changed little in the past few years, despite an increase in the control and accounting procedures for controlled substances as well as increased mandatory education.

Random vibration is being specified for acceptance tests, screening tests, and qualification tests by manufacturers of electronic equipment meant for military applications, because it has been shown that random vibration more closely represents the true environment in which the electronic equipment must operate. In this paper, the methodology of testing an electronic package subjected to random vibration load is illustrated using Joint Electronic Device Engineering Council’s (JEDEC) JESD22-B103B standard. The electronic package mounted at the centre of the printed circuit board was subjected to vibration, variable frequency condition ‘D’ of JEDEC standard for 30 min. After 30 min of random vibration test, the component lead-wires, solderjoints, and PCB were thoroughly inspected for failure. From the observations, it was found that no failure occurred during the test period. The fatigue life of the component, estimated using analytical method, was found to be 96.48 hours.Defence Science Journal, 2009, 59(1), pp.58-62, DOI:http://dx.doi.org/10.14429/dsj.59.1486

The Japanese giant looper, Ascotis selenaria cretacea, is a serious defoliator of tea gardens in Japan. GC-MS analysis of the virgin female extract confirmed the presence of (Z,Z)-6,9-cis-3,4-epoxynonadecadiene. This compound had attracted male moths in a previous random screening test using C17–C23 epoxydienes synthesized in a racemic form. Further GC and HPLC analyses with chiral columns showed that the natural pheromone was composed of 3S,4R and 3R,4S isomers in a ratio of 53:47, although the field evaluation revealed stronger activity of the pure 3R,4S epoxide than of other enantiomeric mixtures. This result indicates that the sexual communication system of this Japanese subspecies differs from that of the species in Israel, which is selectively attracted to an isomer with the opposite configuration. Interestingly, the 3S,4R epoxide attracted another geometric male, Alcis angulifera, in our field tests. (Z,Z,Z)-3,6-9-Nonadecatriene, a parent olefinic compound of the epoxy pheromone, was also identified in the gland extract of A. s. cretacea, but its effect on the attractive activity of the epoxide was not assured in field tests. The amount of the triene increased in the virgin female during photophase and also after decapitation. The epoxy component completely disappeared after decapitation, but could be increased by an injection of subesophageal ganglion extract. The data suggest that the triene is a biosynthetic precursor of the epoxide and that a neuropeptide hormone (PBAN) regulates the epoxydation.

AimThis systematic review aimed to ascertain the diagnostic accuracy (sensitivity and specificity) of screening tests for early detection of type 2 diabetes and prediabetes in previously undiagnosed adults.MethodsThis systematic review included published studies that included one or more index tests (random and fasting tests, HbA1c) for glucose detection, with 75-gram Oral Glucose Tolerance Test (or 2-hour post load glucose) as a reference standard (PROSPERO ID CRD42018102477). Seven databases were searched electronically (from their inception up to March 9, 2020) accompanied with bibliographic and website searches. Records were manually screened and full text were selected based on inclusion and exclusion criteria. Subsequently, data extraction was done using standardized form and quality assessment of studies using QUADAS-2 tool. Meta-analysis was done using bivariate model using Stata 14.0. Optimal cut offs in terms of sensitivity and specificity for the tests were analysed using R software.ResultsOf 7,151 records assessed by title and abstract, a total of 37 peer reviewed articles were included in this systematic review. The pooled sensitivity, specificity, positive (LR+) and negative likelihood ratio (LR-) for diagnosing diabetes with HbA1c (6.5%; venous sample; n = 17 studies) were 50% (95% CI: 42–59%), 97.3% (95% CI: 95.3–98.4), 18.32 (95% CI: 11.06–30.53) and 0.51 (95% CI: 0.43–0.60), respectively. However, the optimal cut-off for diagnosing diabetes in previously undiagnosed adults with HbA1c was estimated as 6.03% with pooled sensitivity of 73.9% (95% CI: 68–79.1%) and specificity of 87.2% (95% CI: 82–91%). The optimal cut-off for Fasting Plasma Glucose (FPG) was estimated as 104 milligram/dL (mg/dL) with a sensitivity of 82.3% (95% CI: 74.6–88.1%) and specificity of 89.4% (95% CI: 85.2–92.5%).ConclusionOur findings suggest that at present recommended threshold of 6.5%, HbA1c is more specific and less sensitive in diagnosing the newly detected diabetes in undiagnosed population from community settings. Lowering of thresholds for HbA1c and FPG to 6.03% and 104 mg/dL for early detection in previously undiagnosed persons for screening purposes may be considered.

“Reduction” in animal use can be achieved by better experimental strategy and improved experimental design. In 1959, one strategy for discovering new drugs involved the random testing of thousands of chemicals in animal models of disease. This strategy was deplored by Russell & Burch in The Principles of Humane Experimental Technique (1959) as being inefficient and inhumane, and has now been almost completely superseded, following fundamental research resulting in an improved understanding of the mechanisms of drug action. Random screening is still done on a large scale, but by using in vitro methods. Good experimental design involves the control of variation. In 1959, it was not clear whether isogenic (inbred or F1 hybrid) strains of mice and rats were more uniform than outbred stocks and whether they should therefore be used preferentially in bioassays. It is now generally accepted that F1 hybrids and inbred strains tend to be more uniform, but, as precision also depends on sensitivity, which is unpredictable, there is no general rule for choosing the best strain for a bioassay. Choice should be based on pilot studies. However, the use of more-uniform, specific pathogen-free animals, which were only just becoming available in 1959, has certainly reduced the number of animals which are used. Other aspects of experimental design, such as the need to avoid bias, have a wide range of applicability; the importance of simplicity and the ability to calculate uncertainty are, apparently, not always appreciated by research scientists. The concept of “reduction” has been useful in focusing attention on the need for improved experimental design. In the long-run, animal welfare legislation and improved training for research scientists should lead to improvements, not only in the way in which animals are kept, but also in the way in which experiments are planned and analysed.

Screening tests are used frequently for control of diseases such as cancer. The increased survival time of screen-detected cases over those that are detected clinically may be due in part to 'lead time', or the length of time by which the disease is diagnosed earlier by screening in the presence or absence of any real extension in survival time. A realistic evaluation of screening needs to assess the true benefit of screening; that is, the length of time by which survival has been extended, beyond merely the time of the advanced diagnosis. The comparison of survival measured from time of entry between cases in a screening arm and in a control arm in randomized studies avoids the lead time bias. If the effects of average lead time and average benefit on survival are additive, these effects can be estimated by recognizing that (a) the difference in survival curves since time of diagnosis confounds benefit and lead time, but (b) the difference in survival curves since time of start of study involves benefit only. The method is evaluated on simulated data for its accuracy and may be used on data from randomized studies.

It is currently recommended that every pregnant woman have a blood glucose screening test for gestational diabetes at 24 to 28 weeks' gestation. Random urine samples are also tested for glucose at each prenatal visit. In 500 consecutive pregnant women, random urine glucose screening values from each prenatal visit were compared with a serum glucose test done at 28 weeks' gestation after ingestion of a 50 gm glucose-containing beverage. Twenty-two patients (4.4%) subsequently were identified as having gestational diabetes. Eighty-five (17%) had some degree of glycosuria, and 19 (3.8%) had severe glycosuria. Only six (27%) of the 22 women with gestational diabetes had any glycosuria. As a screening test for gestational diabetes, glycosuria had a 27% sensitivity and a positive predictive value of only 7.1%. Severe glycosuria, although increased in women with gestational diabetes (P = .0071), occurred in only 18% of cases. Detection of severe glycosuria before 24 weeks' gestation is an indication to do earlier blood glucose screening. After blood glucose screening is done, routinely screening the urine for glycosuria at each prenatal visit does not appear to be clinically useful.

Protocol for a pragmatic trial comparing navigator and automated virtual interventions for guaranteeing adherence to fecal immunochemical testing (NAVIGATE-FIT).

Prothrombin time (PT) and activated partial thromboplastin time (APTT) are two essential coagulation screening tests in various critical disorders including cardiovascular diseases and diabetes. Due to its criticality, accurate assessment of both the parameters are essential and fully automated coagulation analyzers like Erba ECL 760 can be of instrument of choice in this situation. The plasma collected from sodium citrated whole blood is preferred sample for coagulation analysis on fully automated Erba ECL 760. Accuracy, precision and carry over were key quality indicators used for quality check of the instrument and the assay. The L-J charts have been prepared with the available data and results have been analyzed. Wide scope of coagulation tests, ease of procedure, high accuracy and precision, comprehensive presentation of quality control data on the LJ graph, faster 60 samples per hour throughput and random test analysis made ECL 760 as a choice of instrument for coagulation testing requirements. Keywords: APTT(Activated Partial Thromboplastin Time), coagulometer, prothrombin ratio, PT (Prothrombin Time), PT INR(Prothrombin Time International Normalized Ratio) Cite this Article Shivadas Pokkalath, Omkar Kadhane. Evaluation of Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) Reagents on ECL 760 Coagulation Analyzer. Research & Reviews: A Journal of Bioinformatics. 2019; 6(3): 5–11p.

The subject matter of Common Screening Tests should increasingly appeal to the practicing clinician of the 1990s. We are all faced with such outside pressures as peer review and quality assurance, more stringent controls on third-party reimbursement, and the increasingly knowledgeable patient who requests that you do every test possible to diagnose some heretofore occult condition. With the continued inflationary trend in the cost of medical care, we need to pull in the reins on random test ordering. Common Screening Tests aims to educate the physician to order tests more prudently. The book is a collection of position papers previously published in the Annals of Internal Medicine from 1988 to 1991. It begins with an excellent chapter by the editor, David Eddy, MD, PhD, detailing how one should critically evaluate studies of potential tests. For a test to be acceptable for screening purposes, an array of factors must be weighed.

Screening for alcohol and substance use in pediatric trauma patients: A retrospective review